Kim Binger
Impact in
-
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
Papers in
- Oncology 7
- Colorectal Cancer Treatments and Studies 5
- Cancer Treatment and Pharmacology 3
-
- Cancer therapeutics and mechanisms 3
- Ubiquitin and proteasome pathways 1
- Co-authors
- George Wilding (10 shared papers)Dona Alberti (9 shared papers)Rhoda Arzoomanian (8 shared papers)Kendra D. Tutsch (6 shared papers)Rebecca Marnocha (6 shared papers)Jennifer Volkman (3 shared papers)Lynn Van Ummersen (1 shared paper)Jill Kolesar (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Clinical Cancer Research (3 papers)Investigational New Drugs (2 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)Journal of Oncology Pharmacy Practice (1 paper)
- Partner nations
- United StatesSpain
In The Last Decade
Kim Binger
14 papers receiving 468 citations
Peers
Comparison fields: 5 of 65
- Oncology 153
- Cancer Research 69
- Hematology 41
- Molecular Biology 250
- Toxicology 10
Countries citing papers authored by Kim Binger
This map shows the geographic impact of Kim Binger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Binger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Binger more than expected).
Fields of papers citing papers by Kim Binger
This network shows the impact of papers produced by Kim Binger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Binger. The network helps show where Kim Binger may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim Binger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 139 | |
| 2 | Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. | 2000 | 91 |
| 3 | 2005 | 59 | |
| 4 | 2006 | 43 | |
| 5 | 2004 | 41 | |
| 6 | 1998 | 33 | |
| 7 | 2004 | 23 | |
| 8 | 2004 | 18 | |
| 9 | Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. | 2002 | 18 |
| 10 | Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. | 2002 | 18 |
| 11 | 2005 | 2 | |
| 12 | 2002 | 2 | |
| 13 | 2005 | 2 | |
| 14 | 2006 | 1 |
About Kim Binger
Kim Binger is a scholar working on Oncology, Molecular Biology, Genetics, Pharmacology and Organic Chemistry, having authored 14 papers that have together received 490 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (5 papers), Cancer therapeutics and mechanisms (3 papers), Cancer Treatment and Pharmacology (3 papers), Glioma Diagnosis and Treatment (2 papers), Pharmacogenetics and Drug Metabolism (1 paper), Click Chemistry and Applications (1 paper), Ubiquitin and proteasome pathways (1 paper) and Acute Lymphoblastic Leukemia research (1 paper). The work is most often cited by research in Oncology (153 citations), Cancer Research (69 citations), Hematology (41 citations), Molecular Biology (250 citations) and Toxicology (10 citations). Kim Binger has collaborated with scholars based in United States and Spain. Frequent co-authors include George Wilding, Dona Alberti, Rhoda Arzoomanian, Kendra D. Tutsch, Rebecca Marnocha, Jennifer Volkman, Lynn Van Ummersen, Jill Kolesar, Chris Feierabend and Gregory H. Ripple. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Investigational New Drugs, International Journal of Radiation Oncology*Biology*Physics and Journal of Oncology Pharmacy Practice.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.